301201 Chengda Pharmaceuticals
- 21.70
- +0.01+0.05%
Chengda Pharmaceuticals News
November 22nd A-share investment lightning rod︱Changguang Huaxin: Shareholders Guotou Chuangye Ningbo Fund, Yili Suxin, and Nanjing Daofeng plan to collectively reduce their shareholding by no more than 2.01%.
*Shenzhen Coship Electronics: Termination of the application for reorganization and pre-reorganization to the court.
Express News | Chengda Pharmaceutical: Shareholder Qianhai Shengtai plans to reduce their shareholding by no more than 4.22% of the company's shares.
Express News | Chengda Pharmaceuticals: The active pharmaceutical ingredient Daglielin has passed the CDE approval.
Chengda Pharmaceutical: Report for the third quarter of 2024
Chengda Pharmaceutical (301201.SZ) released its performance for the first three quarters, with a net income of 40.3928 million yuan, a decrease of 33.98%.
Chengda Pharmaceutical (301201.SZ) released the third quarter report of 2024, the company's revenue for the first three quarters is 2...
Chengda Pharmaceutical (301201.SZ): has cumulatively repurchased 2.10% of its shares.
Gelonghui October 10th | Chengda Pharmaceutical (301201.SZ) announced that as of September 30, 2024, the company has repurchased a total of 3,244,700 shares of the company through a repurchase special securities account in a centralized auction trading manner, accounting for 2.10% of the company's total share capital. The highest fill price was 22.21 yuan/share, the lowest fill price was 14.63 yuan/share, and the total trade amount was 57.0616 million yuan (excluding trading fees).
Chengda Pharmaceuticals (301201.SZ): At present, the sales price of the company's L-carnitine products is relatively stable, slightly improved compared to the lowest market conditions.
On September 29, Gelonghui reported that Chengda Pharmaceutical (301201.SZ) stated during a specific research session that the current sales price of the company's L-carnitine products is relatively stable, showing a slight improvement compared to the lowest market price. There is still some uncertainty about the future price trends of related products.
Chengda Pharmaceutical: 2024 Semi-Annual Report
Chengda Pharmaceutical: 2024 Semi-Annual Report Summary
Chengda Pharmaceutical (301201.SZ) released its performance for the first half of the year, with a net income of 25.1748 million yuan, a decrease of 14.23%.
Chengda Pharmaceutical (301201.SZ) released its 2024 interim report, with revenue of 0.164 billion...
Express News | Chengda Pharmaceutical: Net income in the first half of 2024 decreased by 14.23% compared to the same period last year.
Chengda Pharmaceutical (301201.SZ): has repurchased 2.03% of its shares to date.
Chengda Pharmaceutical (301201.SZ) announced that as of July 31, 2024, the company has accumulated the repurchase of 3,137,500 shares through a repurchase special securities account using centralized bidding trading method, accounting for 2.03% of the company's current total share capital. The highest fill price was 22.21 yuan/share, and the lowest fill price was 14.63 yuan/share. The total trade amount was 55,266,670.15 yuan (excluding transaction costs).
Chengda Pharmaceutical (301201.SZ) plans to distribute 2 yuan for every 10 shares, with ex-rights and ex-dividend dates on July 10.
Chengda Pharmaceutical (301201.SZ) announced that it plans to distribute equity to all shareholders in 2023: 1 bonus share for every 10 shares held and a cash dividend of 0.5 yuan (tax included) per share.
Chengda Pharmaceutical (301201.SZ): Plans to postpone the "Pharmaceutical intermediate project" and "Active pharmaceutical ingredient project" until December 31, 2024.
On June 28th, Gelunhui reported that Chengda Pharmaceutical (301201.SZ) announced that the 5th Board of Directors and the 5th Supervisory Board meetings were held on June 28th, 2024, and approved the proposal to extend the implementation period of some raised funds investment projects. It was agreed to adjust the implementation period of the raised funds investment projects for "pharmaceutical intermediate projects" and "active pharmaceutical ingredient projects" to December 31, 2024.
Express News | Chengda Pharmaceutical: Heart Failure Indication Program Launched for Stem Cell Treatment of Myocardial Infarctions
Chengda Pharmaceutical (301201.SZ): No orders in progress from the Pfizer API factory
Gelonghui, May 14 | Chengda Pharmaceutical (301201.SZ) said on the investor interactive platform that currently, the company has no orders from the Pfizer API factory. Please refer to the company's announcement for the information to be disclosed.
Chengda Pharmaceutical (301201.SZ): one of the main suppliers of L-carnitine in the world
Gelonghui May 8 丨 Chengda Pharmaceutical (301201.SZ) said on the investor interactive platform that the company is one of the main suppliers of L-carnitine in the world. L-carnitine series products include medicinal grade and food/feed additives. The products that were reduced in the early stages were mainly the food/feed additive L-carnitine. Currently, the sales price market for related products has improved slightly, and there is still some uncertainty about the price trend of related products in the future.
Chengda Pharmaceutical (301201.SZ): Some products use synthetic biotechnology such as enzyme catalysis to improve the quality of related products and reduce production costs
Gelonghui, May 8, 丨 Chengda Pharmaceutical (301201.SZ) said on the investor interactive platform that some of the company's products use synthetic biotechnology such as enzyme catalysis to improve the quality of related products and reduce production costs. The company will then actively promote the application of enzyme catalysis technology and the upgrading of traditional catalytic technology to drive product process upgrading and quality improvement with new technology, providing more possibilities for future drug development. At the same time, the company invested in the establishment of Shanghai Chengjiutai Biomedical Co., Ltd. at the end of 2023, which will help the company lay out the biomedical sector and expand R&D, production and treatment business in the biological cell industry. In fact
Chengda Pharmaceutical (301201.SZ): 2.03% of shares have been repurchased
Gelonghui, May 7, 丨 Chengda Pharmaceutical (301201.SZ) announced that as of April 30, 2024, the company had repurchased a total of 3,137,500 shares of the company's shares through a dedicated securities account, accounting for 2.03% of the company's current total share capital. The highest transaction price was 22.21 yuan/share, the minimum transaction price was 14.63 yuan/share, and the total transaction amount was 55,266.67 million yuan (excluding transaction fees).
Chengda Pharmaceutical (301201.SZ) announced first-quarter results, net profit of 18.644,500 yuan, a decrease of 5.09%
According to the Zhitong Finance App, Chengda Pharmaceutical (301201.SZ) released its report for the first quarter of 2024. The company's revenue was 101 million yuan, a year-on-year decrease of 1.28%. Net profit attributable to shareholders of listed companies was 18.6445 million yuan, a year-on-year decrease of 5.09%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was RMB 10.2459 million, a year-on-year decrease of 26.77%. Basic earnings per share were $0.1215.
Analysis
Price Target
No Data
No Data